Skip to content
Wealthy Investor Report

Wealthy Investor Report

  • Home
  • Domestic
  • Business
  • Money
  • Top News
  • Newsletters
  • Home
  • 2024
  • February
  • 12
  • Gilead to buy CymaBay for $4.3 billion in bets on liver disease treatment
  • FILE PHOTO: Gilead Sciences Inc pharmaceutical company is seen during

FILE PHOTO: Gilead Sciences Inc pharmaceutical company is seen during

FILE PHOTO: Gilead Sciences is seen in Oceanside, California, U.S., April 29, 2020. REUTERS/Mike Blake/File Photo

Post navigation

Gilead to buy CymaBay for $4.3 billion in bets on liver disease treatment

Live Market Pulse

The charting technology is provided by TradingView. Learn how to use theTradingView Stock Screener.

Recent Posts

  • Leaders of global online extortion and exploitation group 764 charged
  • Google CEO Sundar Pichai to take the stand at search antitrust trial
  • Annual gold price forecast tops $3,000 for first time – Reuters poll
  • Etsy tops quarterly revenue estimates on steady demand for apparel, gifts
  • Trump says ‘be patient’ as US economy contracts on tariff disruption

Categories

  • Business
  • Domestic
  • Economy
  • Money
  • Top News
  • Uncategorized
  • Privacy Policy of GBM Media Group, LLC
  • Terms of Service/Use Agreement
  • Disclaimer
  • Contact Us

Copyright © 2025 Wealthy Investor Report | Visionary News Child IMS by Ascendoor | Powered by WordPress.